Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 16 |
| List of Tables | 15 | 2 |
| List of Figures | 17 | 1 |
| Introduction | 18 | 1 |
| Global Markets Direct Report Coverage | 18 | 1 |
| Respiratory Syncytial Virus (RSV) Infections Overview | 19 | 1 |
| Therapeutics Development | 20 | 2 |
| Pipeline Products for Respiratory Syncytial Virus (RSV) Infections Overview | 20 | 1 |
| Pipeline Products for Respiratory Syncytial Virus (RSV) Infections Comparative Analysis | 21 | 1 |
| Respiratory Syncytial Virus (RSV) Infections Therapeutics under Development by Companies | 22 | 4 |
| Respiratory Syncytial Virus (RSV) Infections Therapeutics under Investigation by Universities/Institutes | 26 | 1 |
| Respiratory Syncytial Virus (RSV) Infections Pipeline Products Glance | 27 | 3 |
| Late Stage Products | 27 | 1 |
| Clinical Stage Products | 28 | 1 |
| Early Stage Products | 29 | 1 |
| Respiratory Syncytial Virus (RSV) Infections Products under Development by Companies | 30 | 5 |
| Respiratory Syncytial Virus (RSV) Infections Products under Investigation by Universities/Institutes | 35 | 2 |
| Respiratory Syncytial Virus (RSV) Infections Companies Involved in Therapeutics Development | 37 | 60 |
| Abivax SA | 37 | 1 |
| Ablynx NV | 38 | 1 |
| ADMA Biologics, Inc. | 39 | 1 |
| Agilvax, Inc. | 40 | 1 |
| Aridis Pharmaceuticals LLC | 41 | 1 |
| Artificial Cell Technologies, Inc. | 42 | 1 |
| AstraZeneca Plc | 43 | 1 |
| Aviragen Therapeutics, Inc. | 44 | 1 |
| Bavarian Nordic A/S | 45 | 1 |
| Celltrion, Inc. | 46 | 1 |
| Codagenix, Inc. | 47 | 1 |
| Curevac AG | 48 | 1 |
| DBV Technologies S.A. | 49 | 1 |
| Emergent BioSolutions Inc. | 50 | 1 |
| Enanta Pharmaceuticals, Inc. | 51 | 1 |
| Evec, Inc. | 52 | 1 |
| F. Hoffmann-La Roche Ltd. | 53 | 1 |
| Gene Techno Science Co., Ltd. | 54 | 1 |
| GenVec, Inc. | 55 | 1 |
| Gilead Sciences, Inc. | 56 | 1 |
| GlaxoSmithKline Plc | 57 | 1 |
| Globavir Biosciences, Inc. | 58 | 1 |
| Humabs BioMed SA | 59 | 1 |
| iBio, Inc. | 60 | 1 |
| ILiAD Biotechnologies, LLC | 61 | 1 |
| Ilyang Pharmaceutical Co., Ltd | 62 | 1 |
| Immunovaccine Inc | 63 | 1 |
| Inovio Pharmaceuticals, Inc. | 64 | 1 |
| Johnson &Johnson | 65 | 1 |
| Karyopharm Therapeutics, Inc. | 66 | 1 |
| Kineta, Inc. | 67 | 1 |
| mAbxience S.A. | 68 | 1 |
| MedImmune LLC | 69 | 1 |
| Medivir AB | 70 | 1 |
| Merck &Co., Inc. | 71 | 1 |
| Mucosis B.V. | 72 | 1 |
| Mymetics Corporation | 73 | 1 |
| NanoBio Corporation | 74 | 1 |
| Navigen Pharmaceuticals, Inc. | 75 | 1 |
| NeuClone Pty Ltd | 76 | 1 |
| Novavax, Inc. | 77 | 1 |
| Panacea Biotec Limited | 78 | 1 |
| Profectus BioSciences, Inc. | 79 | 1 |
| Pulmocide Ltd | 80 | 1 |
| Regeneron Pharmaceuticals Inc | 81 | 1 |
| Romark Laboratories, L.C. | 82 | 1 |
| Spider Biotech | 83 | 1 |
| Spring Bank Pharmaceuticals, Inc. | 84 | 1 |
| Takeda Pharmaceutical Company Limited | 85 | 1 |
| TechnoVax, Inc. | 86 | 1 |
| The International Biotechnology Center (IBC) Generium | 87 | 1 |
| Themis Bioscience GmbH | 88 | 1 |
| Trellis Bioscience, Inc. | 89 | 1 |
| Vault Pharma Inc. | 90 | 1 |
| Vaxart Inc | 91 | 1 |
| VaxInnate Corporation | 92 | 1 |
| VBI Vaccines Inc | 93 | 1 |
| Virometix AG | 94 | 1 |
| Visterra, Inc. | 95 | 1 |
| VLP Biotech, Inc. | 96 | 1 |
| Respiratory Syncytial Virus (RSV) Infections Therapeutics Assessment | 97 | 10 |
| Assessment by Monotherapy Products | 97 | 1 |
| Assessment by Combination Products | 98 | 1 |
| Assessment by Target | 99 | 2 |
| Assessment by Mechanism of Action | 101 | 2 |
| Assessment by Route of Administration | 103 | 2 |
| Assessment by Molecule Type | 105 | 2 |
| Drug Profiles | 107 | 142 |
| (human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine Drug Profile | 107 | 1 |
| (influenza (virus like particle) + respiratory syncytial virus) vaccine Drug Profile | 108 | 1 |
| ABX-196 Drug Profile | 109 | 1 |
| AK-0529 Drug Profile | 110 | 1 |
| ALS-8112 Drug Profile | 111 | 1 |
| ALS-8176 Drug Profile | 112 | 3 |
| ALX-0171 Drug Profile | 115 | 3 |
| ANSXRV-14 Drug Profile | 118 | 1 |
| Antisense RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections Drug Profile | 119 | 1 |
| AR-201 Drug Profile | 120 | 1 |
| AX-14 Drug Profile | 121 | 1 |
| AZ-27 Drug Profile | 122 | 1 |
| BTA-585 Drug Profile | 123 | 2 |
| CR-32T Drug Profile | 125 | 1 |
| danirixin Drug Profile | 126 | 2 |
| DPX-RSV Drug Profile | 128 | 2 |
| DT-preF Drug Profile | 130 | 1 |
| EP-023938 Drug Profile | 131 | 1 |
| EV-046120 Drug Profile | 132 | 1 |
| EV-046135 Drug Profile | 133 | 1 |
| GBV-006 Drug Profile | 134 | 1 |
| GNR-007 Drug Profile | 135 | 1 |
| GSK-3003891A Drug Profile | 136 | 1 |
| GSK-3389245A Drug Profile | 137 | 1 |
| GV-2311 Drug Profile | 138 | 2 |
| GXV Drug Profile | 140 | 1 |
| influenza + RSV vaccine Drug Profile | 141 | 1 |
| IYS-21001 Drug Profile | 142 | 1 |
| JNJ-53718678 Drug Profile | 143 | 1 |
| JNJ-61187165AAA Drug Profile | 144 | 1 |
| JNJ-61187191AAA Drug Profile | 145 | 1 |
| JNJ-64400141 Drug Profile | 146 | 1 |
| KIN-1400 Drug Profile | 147 | 2 |
| MEDI-7510 Drug Profile | 149 | 2 |
| MEDI-8897 Drug Profile | 151 | 1 |
| Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections Drug Profile | 152 | 1 |
| Monoclonal Antibody for Respiratory Syncytial Virus Drug Profile | 153 | 1 |
| Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections Drug Profile | 154 | 1 |
| MPE-8 Drug Profile | 155 | 1 |
| MV-012968 Drug Profile | 156 | 1 |
| MVA-RSV Drug Profile | 157 | 1 |
| nitazoxanide CR Drug Profile | 158 | 3 |
| palivizumab biosimilar Drug Profile | 161 | 1 |
| palivizumab biosimilar Drug Profile | 162 | 1 |
| palivizumab biosimilar Drug Profile | 163 | 1 |
| palivizumab biosimilar Drug Profile | 164 | 1 |
| palivizumab biosimilar Drug Profile | 165 | 1 |
| palivizumab biosimilar Drug Profile | 166 | 1 |
| PC-786 Drug Profile | 167 | 1 |
| pertussis [strain BPZE1] vaccine Drug Profile | 168 | 2 |
| presatovir Drug Profile | 170 | 2 |
| Recombinant Protein for Oncology and Infectious Disease Drug Profile | 172 | 1 |
| Recombinant Protein for RSV Infections Drug Profile | 173 | 1 |
| respiratory syncytial virus (virus like particle) vaccine Drug Profile | 174 | 2 |
| respiratory syncytial virus (virus like particle) vaccine Drug Profile | 176 | 1 |
| respiratory syncytial virus (virus like particle) vaccine Drug Profile | 177 | 1 |
| respiratory syncytial virus (virus like particle) vaccine Drug Profile | 178 | 1 |
| respiratory syncytial virus (virus like particle) vaccine Drug Profile | 179 | 1 |
| respiratory syncytial virus (virus like particle) vaccines Drug Profile | 180 | 1 |
| respiratory syncytial virus [strain 98-25147-X] vaccine Drug Profile | 181 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 182 | 2 |
| respiratory syncytial virus vaccine Drug Profile | 184 | 10 |
| respiratory syncytial virus vaccine Drug Profile | 194 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 195 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 196 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 197 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 198 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 199 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 200 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 201 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 202 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 203 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 204 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 205 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 206 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 207 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 208 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 209 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 210 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 211 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 212 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 213 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 214 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 215 | 1 |
| respiratory syncytial virus vaccine Drug Profile | 216 | 1 |
| respiratory syncytial virus vaccine 1 Drug Profile | 217 | 1 |
| respiratory syncytial virus vaccine 1 Drug Profile | 218 | 1 |
| respiratory syncytial virus vaccine 2 Drug Profile | 219 | 1 |
| respiratory syncytial virus vaccine 2 Drug Profile | 220 | 1 |
| respiratory syncytial virus vaccine 3 Drug Profile | 221 | 1 |
| respiratory syncytial virus vaccine 4 Drug Profile | 222 | 1 |
| respiratory syncytial virus-1 vaccine Drug Profile | 223 | 1 |
| RI-002 Drug Profile | 224 | 3 |
| RSV-001 Drug Profile | 227 | 1 |
| RV-521 Drug Profile | 228 | 1 |
| SB-105-A10 Drug Profile | 229 | 1 |
| SB-9200 Drug Profile | 230 | 5 |
| Small Molecule for RSV Drug Profile | 235 | 1 |
| Small Molecules for Respiratory Syncytial Virus Drug Profile | 236 | 1 |
| Small Molecules for RSV and Influenza A Infections Drug Profile | 237 | 1 |
| Small Molecules for RSV Infections Drug Profile | 238 | 1 |
| Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections Drug Profile | 239 | 1 |
| suptavumab Drug Profile | 240 | 1 |
| SynGEM Drug Profile | 241 | 2 |
| TRL-3D3 Drug Profile | 243 | 1 |
| TVX-004IP Drug Profile | 244 | 1 |
| verdinexor Drug Profile | 245 | 1 |
| VIS-RSV Drug Profile | 246 | 1 |
| VMT-3 Drug Profile | 247 | 1 |
| VPI-251 Drug Profile | 248 | 1 |
| Respiratory Syncytial Virus (RSV) Infections Dormant Projects | 249 | 5 |
| Respiratory Syncytial Virus (RSV) Infections Discontinued Products | 254 | 1 |
| Respiratory Syncytial Virus (RSV) Infections Product Development Milestones | 255 | 11 |
| Featured News &Press Releases | 255 | 1 |
| Oct 31, 2016: ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus | 255 | 1 |
| Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine | 255 | 1 |
| Oct 13, 2016: Immunovaccine Announces Positive Phase 1 Topline Data for DepoVax based Respiratory Syncytial Virus Vaccine Candidate | 256 | 1 |
| Sep 29, 2016: Enanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus at the 10th Annual Respiratory Syncytial Virus Conference | 257 | 1 |
| Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium | 257 | 1 |
| Sep 27, 2016: Ansun BioPharma Announces Two Publications Showing Inhibitory Effects of DAS181 on Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) | 258 | 1 |
| Sep 23, 2016: Researchers to Present Data on Immunovaccine Infectious Disease Pipeline at Three International Conferences | 258 | 1 |
| Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults | 259 | 1 |
| Aug 11, 2016: Navigen Announces $3MM Phase II NIH SBIR Award to Support the Development of its Anti-RSV Compound to Prevent and Treat RSV Infections in Children and Adults | 260 | 1 |
| Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial | 261 | 1 |
| Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial | 261 | 1 |
| Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine | 262 | 1 |
| Jul 06, 2016: Immunovaccine Announces Positive Interim Phase 1 Data for DepoVax-Based Respiratory Syncytial Virus Vaccine Candidate | 262 | 1 |
| Jun 28, 2016: Vaxart Initiates Clinical Development of First Oral RSV Vaccine | 263 | 1 |
| Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program | 263 | 3 |
| Appendix | 266 | 2 |
| Methodology | 266 | 1 |
| Coverage | 266 | 1 |
| Secondary Research | 266 | 1 |
| Primary Research | 266 | 1 |
| Expert Panel Validation | 266 | 1 |
| Contact Us | 266 | 1 |
| Disclaimer | 267 | 1 |